A rare mutation in the LRRK2 gene found in 17 individuals with Parkinson’s disease or a family history of Parkinson’s — all of European ancestry with a shared genetic background — appears to be a likely cause of the condition, according to a study of thousands of people. The…
Older adults with tremor are three times more likely than those in the general elderly population to develop Parkinson’s disease — especially if they act out their dreams while sleeping or experience new-onset rest tremor — a study from China has found. That study aimed “to explore predictive factors”…
NDC-0524, an experimental antibody that Nitrase Therapeutics is developing as a treatment for people with Parkinson’s disease, is expected to enter clinical testing in the fourth quarter of 2025, or before the end of the year, according to a company press release. The antibody, which targets nitrated…
Parkinson’s disease can lead to early retinal changes — alterations in the thin layer at the back of the eye, known as the retina, that’s responsible for detecting light and sending visual signals to the brain — that can be revealed with the use of a simple eye test,…
Researchers for the first time visualized how PINK1, a protein linked to early-onset Parkinson’s disease, binds to mitochondria and how it’s switched on to protect these energy-producing structures when they’re damaged. Using a high-resolution microscope to map the structure of the human version of PINK1 bound to damaged mitochondria,…
Neurons, or nerve cells, that release a signaling molecule called glutamate within the enteric nervous system — a network of nerve cells embedded in the gut wall — play a crucial role in regulating bowel movements, according to a Stanford University study that ultimately could lead to new ways to…
The first patient has been dosed in Gain Therapeutics‘ clinical trial of GT-02287, an investigational, oral small molecule being developed for treating Parkinson’s disease. With several locations open in Australia, the Phase 1b clinical trial (NCT06732180) is still recruiting up to 20 adults, ages 30-85, who’ve been…
A rare nerve disorder may offer clues to potential Parkinson’s disease treatment targets, a mouse study showed. In giant axonal neuropathy (GAN), buildup of neurofilament proteins trap several cellular organelles and proteins, preventing nerve cells from clearing and recycling waste, the study found. Because neurofilament proteins have also been…
Right Brain Bio is repurposing the approved therapy RB-190 as a treatment for Parkinson’s disease — and is now preparing to seek U.S. Food and Drug Administration (FDA) clearance to test the anticancer medication for this indication in a Phase 2 clinical trial. The company intends to file…
Note: This story was updated March 17, 2025, to correct the attribution of quotes to Sonya Dumanis, PhD, deputy director of Aligning Science Across Parkinson’s. The Aligning Science Across Parkinson’s (ASAP) initiative is investing $6 million in research grants to support the development of new tools — including cell…
Get regular updates to your inbox.
